Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Enquête sur les effets du nitrate alimentaire et du sexe sur le dysfonctionnement vasculaire induit par le vaccin COVID-19 chez des hommes et des femmes en bonne santé (DiNOVasc-COVID-19)

22 septembre 2026 mis à jour par: Queen Mary University of London

Une étude parallèle en double aveugle, randomisée et contrôlée par placebo pour étudier l'effet du nitrate alimentaire et du sexe sur le dysfonctionnement vasculaire induit par le vaccin COVID-19 chez des hommes et des femmes en bonne santé

Inorganic nitrate can protect blood vessels from the damage that occurs during cardiovascular disease. Early experimental work suggests that nitrate-induced improvements in vascular function relate to the suppression of inflammatory pathways. Whether this protection against inflammation-induced damage to the blood vessel wall might also be functional in the setting of COVID-19 vaccination will be investigated.

Vascular function will be assessed before and after the healthy participant has received their COVID-19-vaccination. Whether there might be differences in the response to the vaccine between the sexes and whether a dietary nitrate intervention impacts upon the effects of vaccination will be investigated.

The study is in two parts:

Part A: To assess sex differences in the vascular response to COVID-19 vaccination.

Part B: To assess whether inorganic nitrate, in the form of dietary inorganic nitrate supplementation compared to placebo control, can raise circulating plasma nitrite levels and thereby prevent the systemic inflammation that causes vascular dysfunction.

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Description détaillée

Whether the COVID-19 vaccine can be used to study endothelial dysfunction and whether inorganic nitrate might be useful in restoring the function of the endothelium in a scenario simulating the COVID-19 infection setting will be investigated.

Furthermore, sex differences in the vascular response to the COVID-19 vaccination will be investigated.

Design: A prospective randomised, double-blind, placebo-controlled trial.

Target population: A total of 98 healthy participants will be recruited. Part A: 30 participants (15 male, 15 female.) Part B: 68 participants (34 intervention, 34 placebo). Participants will be recruited prior to receiving the COVID-19 vaccination, via Barts Health NHS Trust approved vaccination hubs.

Setting: Equal numbers of healthy male and female volunteers, aged between 18 and 60 years of age, will be recruited. Following recruitment, participants will undergo baseline measurements of vascular function of flow mediated dilatation (FMD) and pulse wave analysis/velocity (PWA, PWV), in addition to haematological and clinical biochemical analyses. Volunteers will then be randomised into one of the 2 study Parts (Part A: sex differences in vascular response to COVID-19 vaccine, Part B: influence of dietary nitrate upon vascular responses to COVID-19 vaccine). If randomised to Part B, volunteers will be treated with 3 days of either 4-5mmol nitrate-containing beetroot juice or placebo. If randomised to Part A, the volunteers will not receive an intervention. On day 3, all participants will receive their COVID-19 vaccine. At 8±2hours after the vaccine, the participants will undergo repeat measurements of vascular function. A quality of life questionnaire will be obtained 28 days after the vaccine has been administered.

Intervention: All volunteers will receive COVID-19 vaccination in Part A and Part B. In Part B of the study, volunteers will be randomised in a 1:1 fashion to receive either nitrate-containing beetroot juice (4-5mmol nitrate) or nitrate-deplete placebo.

The study will take place in the Clinical Research Centre at The William Harvey Research Institute.

Analysis: For the analysis of Part A linear regression will be used to compare change in vascular dysfunction from pre- to post-vaccination between the sexes, unadjusted and adjusted for important risk factors including age, BMI and baseline vessel diameter. For Part B analysis of covariance (ANCOVA) will be used to compare change in vascular dysfunction from pre- to post-vaccination between dietary nitrate and placebo control groups adjusting for pre-vaccination level, and to compare change in plasma nitrite between dietary nitrate and placebo control groups adjusting for baseline nitrite level.

Type d'étude

Interventionnel

Inscription (Réel)

42

Phase

  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • London, Royaume-Uni, EC1M 6BQ
        • The William Harvey Research Institute

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 60 ans (Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Healthy volunteers with a booking for COVID-19 vaccination slot as per government guidelines
  2. Aged 18-60
  3. Volunteers who are willing to sign the consent form

Exclusion Criteria:

  1. Aged <18 or >60 years
  2. Healthy subjects unwilling to consent
  3. Pregnant, or any possibility that a subject may be pregnant
  4. History of any serious illnesses, including recent infections or trauma
  5. Subjects taking systemic medication (other than the oral contraceptive pill)
  6. Subjects with self-reported use of mouthwash or tongue scrapes
  7. Subjects with recent (2 weeks) or current antibiotic use
  8. Subjects with a history, or recent treatment of (within last 3 months) any oral condition (excluding caries), including gingivitis, periodontitis and halitosis
  9. Subjects with a history of COVID-19 vaccination
  10. Subjects with any history of a blood-borne infectious

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Partie A : Hommes volontaires sains

COVID-19 vaccine as offered by NHS England

Expérimental: Partie A : Femmes volontaires en bonne santé

COVID-19 vaccine as offered by NHS England

Comparateur actif: Part B: Nitrate-rich beetroot juice

Dietary Supplement: Concentrate beetroot Juice (70 ml) containing ~5mmol of inorganic nitrate

COVID-19 vaccine as offered by NHS England

Beetroot juice containing approximately 5mmol/l nitrate

Comparateur placebo: Part B: Nitrate-deplete beetroot juice

Dietary Supplement: Concentrate beetroot Juice (70 ml) which is nitrate-depleted

COVID-19 vaccine as offered by NHS England

Beetroot juice with nitrate removed

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Comparison of change in FMD from baseline between the sexes after COVID-19 vaccination
Délai: Up to 28 days

A measurement of brachial artery diameter using ultrasound (FMD, flow mediated dilatation) will be conducted at visits 2 and 3 (i.e. pre- and post-vaccine). This outcome measure will compare these 2 measurements, and change in FMD will be calculated as subtracting the value collected at visit 3 from visit 2, and expressed as a percentage (%). Comparisons will then be made between the sexes (i.e. males vs females) in Part A.

Up to 28 days
Comparison of change in FMD from baseline after COVID-19 vaccination following inorganic nitrate versus placebo supplementation
Délai: Up to 28 days

A measurement of brachial artery diameter using ultrasound (FMD, flow mediated dilatation) will be conducted at visits 2 and 3 (i.e. pre- and post-vaccine). This outcome measure will compare these 2 measurements, and change in FMD will be calculated as subtracting the value collected at visit 3 from visit 2, and expressed as a percentage (%). Comparisons will then be made between intervention and placebo in Part B.

Up to 28 days
Comparison of change in plasma [NO2-] following inorganic nitrate versus placebo supplementation
Délai: Up to 28 days

Quantification of [NO2-] will be made using ozone chemiluminescence. Samples of blood, urine and saliva will be acquired at visit 2 and visit 3 (i.e. pre- and post-vaccine). Measurement of [NO2-] will be made in all matrices at both timepoints, and a comparison will be made (for this we plan on using 2-way ANOVA, using GraphPad Prism statistics package) to compare time and intervention.

Up to 28 days

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Comparison between the sexes in the systemic inflammatory response to COVID-19 vaccination
Délai: Up to 28 days

Comparisons of the inflammatory response will be made using a combination of clinical haematology and chemistry to assess leukocyte sub-types, and inflammatory markers such as C-reactive protein. Samples of blood will be acquired at visit 2 and visit 3 (i.e. pre- and post-vaccine). Comparison will be made (for this we plan on using 2-way ANOVA, using GraphPad Prism statistics package) to compare time and intervention.

Up to 28 days
Comparison between nitrate and placebo with respect to inflammatory cell activation state
Délai: Up to 28 days

Comparisons of the inflammatory cell activation state will be made through the assessment of inflammatory cytokines and chemokines (bead array analyser). Samples of blood plasma will be acquired at visit 2 and visit 3 (i.e. pre- and post-vaccine). Comparison will be made (for this we plan on using 2-way ANOVA, using GraphPad Prism statistics package) to compare time and intervention.

Up to 28 days
Comparison between nitrate and placebo with respect to circulating inflammatory mediators
Délai: Up to 28 days

Comparisons of the inflammatory mediators will be made through the assessment of inflammatory cytokines and chemokines (bead array analyser). Samples of blood plasma will be acquired at visit 2 and visit 3 (i.e. pre- and post-vaccine). Comparison will be made (for this we plan on using 2-way ANOVA, using GraphPad Prism statistics package) to compare time and intervention.

Up to 28 days
Comparison between nitrate and placebo with respect to platelet function during systemic inflammation
Délai: Up to 28 days

Comparisons of the platelet function will be made through the use of a platelet aggregometer and flow cytometry. Samples of citrate containing whole blood will be acquired at visit 2 and visit 3 (i.e. pre- and post-vaccine). Comparison will be made (for this we plan on using 2-way ANOVA, using GraphPad Prism statistics package) to compare time and intervention.

Up to 28 days
Comparison between nitrate and placebo with respect to endothelium independent vasodilation of the brachial artery
Délai: Up to 28 days

Comparisons of endothelium independent vascular function will be made through the use brachial artery ultrasound and sublingual glyceryl trinitrate. Vascular ultrasound will be conducted at visit 2 and visit 3 (i.e. pre- and post-vaccine). Comparison will be made (for this we plan on using 2-way ANOVA, using GraphPad Prism statistics package) to compare time and intervention.

Up to 28 days

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

10 mai 2021

Achèvement primaire (Réel)

2 décembre 2025

Achèvement de l'étude (Réel)

2 décembre 2025

Dates d'inscription aux études

Première soumission

6 mai 2021

Première soumission répondant aux critères de contrôle qualité

14 mai 2021

Première publication (Réel)

17 mai 2021

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

25 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

22 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 21/SC/0154

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .